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Abstract
Background: DNA recombination technologies such as the Cre/LoxP system advance modern biological research by
allowing conditional gene regulation in vivo. However, the precise targeting of a particular cell type at a given time point
has remained challenging since spatial specificity has so far depended exclusively on the promoter driving Cre recombinase
expression. We have recently established split-Cre that allows DNA recombination to be controlled by coincidental activity
of two promoters, thereby increasing spatial specificity of Cre-mediated DNA recombination. To allow temporal control of
split-Cre-mediated DNA recombination we have now extended split-Cre by fusing split-Cre proteins with the tamoxifen
inducible ERT2 domain derived from CreERT2.
Methodology/Principal Findings: In the split-CreERT2 system, Cre-mediated DNA recombination is controlled by two
expression cassettes as well as the time of tamoxifen application. By using two independent Cre-dependent reporters
in cultured cells, the combination of NCre-ERT2+ERT2-CCre was identified as having the most favorable properties of
all constructs tested, showing an induction ratio of about 10 and EC50-values for 4-hydroxy-tamoxifen of 10 nM to
70 nM.
Conclusions/Significance: These characteristics of split-CreERT2 in vitro indicate that split-CreERT2 will be well suited for
inducing DNA recombination in living mice harboring LoxP-flanked alleles. In this way, split-CreERT2 will provide a new tool
of modern genetics allowing spatial and temporal precise genetic access to cell populations defined by the simultaneous
activity of two promoters.
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Introduction
DNA recombination technologies such as the Cre/LoxP system
have advanced and refined the analysis of gene and cell functions
in mice [1–4]. In contrast to classical in vivo ‘‘knockout’’ strategies,
which result in a complete deletion of gene function in the whole
organism, this conditional gene targeting technology enables a cell
type-specific deletion of genes by driving the expression of Cre
recombinase under the control of a cell type-specific promoter
[1,5,6]. In addition, the Cre/LoxP system has been used for fate
mapping and for cell ablation in vivo [7–12].
Despite the enormous success of cell-specific gene targeting
using Cre/LoxP, two major limitations are inherent to this system:
1) the time of recombination is solely determined by the time of
onset of the promoter activity driving Cre expression and can not
be controlled experimentally; 2) the specificity of the promoter
used to drive Cre expression is often not sufficient to selectively
target a specific cell population. To overcome the first limitation,
inducible forms of the Cre recombinase were developed to allow
for temporally controlled somatic mutagenesis thereby circum-
venting problems arising from constitutive Cre recombinase
activity [2]. The most widely used version of inducible Cre is
CreERT2 [13], in which Cre is fused to a mutated ligand binding
domain of the human estradiol receptor (ERT2), which does not
bind endogenous estradiol but is highly sensitive to nanomolar
concentrations of tamoxifen or its metabolite 4-hydroxy-tamoxifen
(4OHT) [13]. In stably transfected F9 murine embryonal
carcinoma cells, the EC50 for 4OHT was found to be 6 nM
[13]. In the absence of the inducer tamoxifen, the fusion protein is
trapped in the cytosol by binding to heat shock proteins.
Administering the synthetic ligand tamoxifen releases CreERT2
from this complex, allowing CreERT2 to enter the nucleus and
excise LoxP-flanked DNA regions [2].
An enhanced precision of spatial control of DNA recombination
can be achieved by controlling Cre expression and activity not by
a single promoter, but by the combination of two promoters
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[14]. Following this rational, we recently developed the ‘‘split-Cre
system’’ based on the functional complementation of Cre protein
fragments [15]. The coding sequence of Cre recombinase was
divided into two parts (NCre and CCre) which were both fused to
constitutive GCN4 protein-protein interaction domains. Placing
both split-Cre proteins under the control of two different
promoters, we observed DNA recombination in the brain of
living transgenic mice in a cell population, which was defined by
the simultaneous activity of the human glial fibrillary acidic
protein promoter as well as the mouse proteolipid protein
promoter [15].
In the present work, we combined the temporal control by an
inducible Cre with the precise spatial control of split-Cre. We have
developed a conditional and inducible DNA recombination system
for cell populations defined by the simultaneous activity of two
promoters. The ERT2 tamoxifen binding domain of CreERT2
was added to the split-Cre system to achieve tamoxifen inducibility
of split-Cre mediated DNA recombination. This strategy was
named split-CreERT2. We show that after transfection of cultured
cells, split-CreERT2 allows induction of DNA recombination by
4OHT with little activity in the absence of 4OHT. Thus, split-
CreERT2 combines temporal control and two-dimensional spatial
control of DNA recombination and should enable further
refinement of the analysis of gene and cell function in living mice
and other organisms.
Results
Based on our previous results with functional complementation
of split-Cre proteins [15], we constructed inducible versions of
split-Cre proteins by fusing the tamoxifen inducible ERT2-domain
to each of the termini of both NCre and CCre (Fig. 1). The ‘‘split-
CreERT2’’ proteins obtained were termed NCre-ERT2, CCre-
ERT2, ERT2-NCre or ERT2-CCre (Fig. 1). We refer to these
constructs below using the abbreviations NE, CE, EN and EC,
respectively (the original NCre and CCre [15] will be referred to as
N and C, respectively; Fig. 1). In a first attempt to determine
whether complementation of these fusion proteins can reconstitute
Cre-dependent DNA recombination activity and whether this
activity is dependent on tamoxifen application, CHO cells were
transfected with combinations of split-Cre and split-CreERT2
proteins and incubated in the absence or presence of 4OHT. To
detect DNA recombination a CMV-LoxP-STOP-LoxP-firefly
luciferase reporter plasmid was cotransfected and luciferase
activity was measured (Fig. 2A). Luciferase activity was normalized
to luciferase activity in N+C transfected cells cultured in the
absence of 4OHT, which was set as 100%. Cells transfected with
full-length Cre recombinase showed 234625% (n=10) of the
activity of N+C, confirming our previous results [15]. In contrast,
all cells transfected with ERT2-tagged proteins showed a lower
luciferase activity even after application of 4OHT compared to
N+C transfected cells and the different combinations of split-
CreERT2 proteins showed unequal activity (Fig. 2A). Western
Blot analysis revealed expression of all constructs (Fig. 3),
suggesting that the differences in activity are due to functional
differences and not due to lack of expression. Nevertheless, several
combinations of split-CreERT2 proteins showed inducibility of
DNA recombination by 4OHT (Fig. 2A) and an induction ratio
was calculated as [luminescence in the presence of 4OHT/
luminescence in the absence of 4OHT] (Fig. 2B). This analysis
revealed that the combination of NE+CE, NE+EC and EN+CE
can be induced best by 4OHT (Fig. 2B). However, while e.g.
NE+CE shows the highest inducibility (Fig. 2B), the total activity
even in the presence of 4OHT is low (Fig. 2A). Therefore, a
functional index was defined as [induction ratio6luminescence in
the presence of 4OHT] to asses which combination of split-
CreERT2 proteins combines the favorable properties of high
activity and high inducibility (Fig. 2C). This analysis indicated that
NE+CE and NE+EC are the best combinations (Fig. 2C).
Transgenic mice used for conditional gene targeting experi-
ments normally harbor only a few LoxP-recombination sites,
which are stably integrated within the genomic DNA. However, in
our luciferase reporter experiments the reporter plasmids were
transiently transfected resulting in a high number of LoxP-sites
localized on plasmids. To study split-CreERT2-mediated recom-
bination in a cell culture system containing only a few LoxP-sites
stably integrated within the genomic DNA, resembling more
realistically the situation in transgenic mice, PC12 20.4 cells were
used [16]. PC12 20.4 cells contain a stably integrated CMV-LoxP-
STOP-LoxP-EGFP cassette and report Cre-dependent DNA
recombination by expression of EGFP [16]. These cells were
transfected with the different combinations of split-CreERT2
plasmids, incubated in the absence and presence of 4OHT and
split-CreERT2 dependent DNA recombination was analyzed
using flow cytometry (Fig. 4A). Cells transfected with full-length
Cre recombinase showed 219613% (n=27) of the activity of
N+C, again confirming our previous results [15]. The different
combinations of split-CreERT2 proteins showed variable levels of
activity (Fig. 4A) and inducibility (Fig. 4B) similar to the results
obtained in CHO cells transiently transfected with the reporter
plasmids (Fig. 2). The calculation of the functional index (Fig. 4C)
Figure 1. Split-CreERT2 constructs. The original, non-inducible split-Cre proteins NCre and CCre have recently been described [15]. To generate
NCre-ERT2 and CCre-ERT2, the ERT2-domain was fused to the C-terminus of NCre and CCre, respectively. Vice versa, the ERT2-domain was fused to
the N-terminus of NCre and CCre to obtain ERT2-NCre and ERT2-CCre, respectively. The abbreviations for the different constructs used in this paper
are given in brackets. The thick vertical line at the N-terminus of all constructs denotes the position of the corresponding immunotag (NCre
containing constructs: Flag-tag; CCre containing constructs: Myc-tag).
doi:10.1371/journal.pone.0008354.g001
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properties, thereby confirming the data obtained by luciferase
assays in CHO cells. Interestingly, NE+CE showed less activity in
PC12 20.4 cells than in CHO cells, resulting in a low functional
index despite substantial inducibility.
Based on these results, we further characterized the properties
of the combination NE+EC. CHO cells were transfected with
NE+EC along with a CMV-LoxP-STOP-LoxP-EGFP-reporter
plasmid and a vector expressing nuclear DsRed as a transfection
control (Fig. 5A, B). In the absence of 4OHT, transfected cells
could readily be identified by nuclear staining with DsRed,
however, no EGFP could be detected (Fig. 5A). In contrast, after
application of 4OHT (1 mM), DsRed-positive cells were also
positive for EGFP indicating successful recombination of the
reporter plasmid (Fig. 5B). Furthermore, expression of NE and EC
was analyzed by immunocytochemical staining for the Flag- and
Myc-tag, respectively (Fig. 5C–F). After application of 4OHT,
cells expressing both NE and EC could be identified by nuclear
localization of the respective signals for the Flag- and Myc-tag
(Fig. 5C, D). Most of these cells also expressed EGFP (Fig. 5E).
Quantitative analysis revealed that 86.1% of cells positive for both
NE and EC were also positive for EGFP (n=122 cells analyzed
from 2 independent stainings).
To analyze the dose-response relationship for both the amount
of transfected plasmid DNA and for the concentration of 4OHT,
we performed luciferase assays on CHO cells (Fig. 6A, B) and flow
cytometry on PC12 20.4 cells (Fig. 6C, D). First, cells were
transfected using different amounts of NE and EC plasmids and
incubated in the presence or absence of 4OHT (Fig. 6A, C). In the
absence of 4OHT, only minor reporter gene expression could be
detected with the plasmid concentrations used. In contrast, in the
presence of 4OHT, a dose dependent increase in reporter gene
expression was observed (Fig. 6A, C). From this data, the EC50
value for the amount of transfected plasmids was calculated as
1.460.7 ng/well and 89656 ng/well (n=3–5 experiments each
Figure 2. Split-CreERT2 mediated DNA recombination analyzed
in CHO cells by luciferase assays. A: CHO cells cultured in 96-well cell
culture plates were transfected with the different combinations of split-
CreERT2 plasmids (for abbreviations see Fig. 1; 100 ng of each plasmid/
well) and cultured in the absence (control, open bars) or presence of
4OHT (1 mM, black bars). Cre-dependent DNA recombination was
analyzed by cotransfection of a CMV-LoxP-STOP-LoxP-luciferase reporter
plasmid. Luciferase activity was normalized to luciferase activity in N+C
transfectedcellsculturedintheabsenceof4OHT.B:Inductionratioswere
calculated as [(luciferase activity in the presence of 4OHT)/(luciferase
activity in the absence of 4OHT)]. The dotted line denotes a ratio of 1,
which means no induction. C: A functional index of each combination of
split-CreERT2 proteins was calculated as [(induction ratio)6(luciferase
activity in the presence of 4OHT)]. This functional index is highest if the
combination of split-CreERT2 proteins shows high inducibility and high
activity in the presence of 4OHT. The figure shows data from 3
independent experiments, each of which was performed at least in
triplicate. n.c.: not calculated.
doi:10.1371/journal.pone.0008354.g002
Figure 3. Western Blot analysis of the expression of the
different split-CreERT2 constructs. CHO cells were transfected
with the different combinations of split-CreERT2 plasmids as indicated.
Expression of N, NE and EN was analyzed by immunoblotting with anti-
Flag antibodies, whereas C, CE and EC were detected by anti-Myc as
well as anti-Cre antibodies. GAPDH was used as a loading control. The
observed sizes of the proteins were as expected (N: 14.8 kDa; NE:
50.1 kDa; EN: 51.1 kDa; C: 41.6 kDa; CE: 77.0 kDa; EC: 78.0 kDa; GAPDH:
35.9 kDa).
doi:10.1371/journal.pone.0008354.g003
Split-CreERT2
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cytometry assays, respectively. Similarly, a dose dependent
increase in reporter gene expression was observed with increasing
concentrations of 4OHT (Fig. 6B, D). From these data, the EC50
value for 4OHT was calculated as 1065 nM and 68650 nM for
luciferase and flow cytometry assays, respectively (n=3 experi-
ments each of which was performed in triplicate. The values
Figure 4. Split-CreERT2 mediated DNA recombination ana-
lyzed in PC12 20.4 cells by flow cytometry. A: PC12 20.4 cells,
which harbor a stably transfected CMV-LoxP-STOP-LoxP-EGFP reporter
cassette, were cultured in 24-well cell culture plates and transfected
with the different combinations of split-CreERT2 plasmids (for
abbreviations see Fig. 1; 400 ng of each plasmid/well) and cultured in
the absence (control, open bars) or presence of 4OHT (1 mM, black
bars). B: Induction ratios were calculated as in Fig. 2. The dotted line
denotes a ratio of 1, which means no induction. C: A functional index of
each combination of split-CreERT2 proteins was calculated as indicated
in the legend of Fig. 2. The figure shows data from 8 independent
experiments, each of which was performed at least in triplicate. n.c.: not
calculated.
doi:10.1371/journal.pone.0008354.g004
Figure 5. Immunocytochemical analysis of the split-CreERT2
protein combination NCre-ERT2 + ERT2-CCre (NE+EC). A, B: CHO
cells cultured in 24-well cell culture plates were transfected with NE+EC
(150 ng of each plasmid/well) along with a reporter plasmid which
expresses EGFP only after Cre-mediated DNA recombination (400 ng/
well) and an expression vector coding for nuclear DsRed (100 ng/well;
shown in red). Cells were cultured in the absence (A) or presence of
4OHT (1 mM, B). Recombination is detected by EGFP reporter expression
(green; visualized by immunostaining using anti-GFP-antibodies). In
blue, DAPI-staining of all nuclei is shown. C–F: Immunocytochemical
confirmation of expression of NE and EC and of recombination in NE+EC
transfected cells after application of 4OHT. CHO cells were transfected
with NE+EC (400 ng of each plasmid/well) along with a reporter
plasmid which expresses EGFP only after Cre-mediated DNA recombi-
nation (400 ng/well) and cultured in the presence of 4OHT (1 mM). NE
(C), EC (D) and EGFP (E) were visualized by immunostaining for Flag-tag,
Myc-tag or GFP, respectively, and detected by Cy5-, Cy3- or Cy2-
conjugated secondary antibodies. F shows the merged images with NE
in magenta, EC in red, EGFP in green and DAPI in blue. Note the
additional nuclei stained with DAPI but not by anti-Flag- or anti-Myc-
antibodies, which are also negative for EGFP. The bar in F corresponds
to 20 mm and applies to all panels.
doi:10.1371/journal.pone.0008354.g005
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significantly different, p=0.313, t-test).
Discussion
In the current work, split-CreERT2 is presented as a new tool
adding temporal control of DNA recombination to the recently
described split-Cre system [15]. The ERT2-domain [13] was fused
to the N-terminus or the C-terminus of the constitutively active
NCre- and CCre-proteins [15]. Three parameters were assessed to
dissect the functional properties of split-CreERT2 proteins: 1) low
recombination in the absence of tamoxifen (no leakage); 2) high
activity of recombination in the presence of tamoxifen; 3) a high
induction ratio. When the different combinations of split-
CreERT2 proteins were analyzed, not all versions showed the
same properties regarding these criteria. Generally, the reporter
gene expression from split-CreERT2 proteins was lower than that
from the non-inducible forms of split-Cre (N+C; Fig. 2A, 4A),
indicating lower recombination activity of split-CreERT2 com-
pared to split-Cre in cell culture, which might hamper the efficient
targeting of cells in living mice. However, a similarly reduced
recombination activity of split-Cre was observed when compared
to full-Cre in vitro [15]. Nevertheless, in transgenic mice split-Cre
induced robust reporter gene activation, which was probably more
limited by mosaic transgene expression rather than by split-Cre
efficiency itself [15]. These findings may indicate that the situation
in vitro and in vivo differs e.g. in expression kinetics, expression
levels, kinetics of activation and DNA recombination. Whether the
lower DNA recombination activity of split-CreERT2 in cell
culture will limit DNA recombination in mice in vivo remains to be
determined experimentally by generating appropriate transgenic
mice.
The maximal induction ratio observed for split-CreERT2 was
about 10 (Fig. 2B, 4B), which is in the same range as the reported
in vitro induction ratios of CreERT and CreERT2 (about 7 to 15;
[13,17]). As both CreERT and CreERT2 have been used
successfully in mice in vivo, this suggests that the induction ratios
found for split-CreERT2 will be sufficient for successful use in
living animals. However, while a high induction ratio is necessary
for successful use of split-CreERT2, a high total activity in the
presence of 4OHT is also needed. For this reason, we calculated a
‘‘functional index’’ as the product of induction ratio and activity
(Fig. 2C, 4C). This analysis indicated that the split-CreERT2
variants NE+EC performed best.
The lack of recombination activity from the combination of
N+CE was unexpected since the fusion of ERT2 to the C-terminal
end of CCre is highly comparable to the well established
CreERT2 protein. The cloning strategy resulted only in the
exchange of three amino acids for two (LEPRTS) in the region
connecting the Cre coding sequence to the ERT2 coding
sequence. However, the other combinations of CE (with NE and
EN) also showed very little recombination activity. This suggests
that the ERT2 domain on the C-terminus of CCre might spatially
interfere with the GCN4 protein-protein interaction domain of the
NCre constructs or of CCre-ERT2 itself, as this interaction
domain is not present in CreERT2 [13]. In contrast, in the case of
N+EC, application of 4OHT actually decreased reporter gene
activity, which was already high in the absence of 4OHT. The
high basal reporter gene activity might indicate that EC is not
completely trapped within the cytosol in the absence of 4OHT,
thereby allowing functional complementation with N in the
nucleus even in the absence of 4OHT. However, the reason for
the decrease of reporter gene activity after application of 4OHT
remains obscure. Most likely, the conformational change in EC
induced by binding of 4OHT impairs the interaction with N,
thereby reducing functional complementation and DNA recom-
bination activity.
The successful use of split-CreERT2 in living mice will require
that tamoxifen reaches the targeted cells in sufficient concentra-
tions to induce split-CreERT2 nuclear translocation by binding to
the ERT2-domain. An EC50-value of about 10 nM to 70 nM
4OHT for luciferase and flow cytometry assays, respectively, was
determined for NE+EC. While the concentration of tamoxifen or
4OHT within tissues after application of tamoxifen has not been
determined in mice in vivo, indirect evidence indicates that
tamoxifen concentrations will not be limiting. For the well
established CreERT and CreERT2, an EC50 of 20 nM and
6 nM 4OHT was determined in in vitro assays similar to those used
here [13]. In addition, by analyzing DNA recombination directly
by Southern blotting, EC50 values.100 nM have been deter-
mined in embryonic stem cells for CreERT and CreERT2 [17].
Figure 6. Detailed characterization of the split-CreERT2 protein
combination NCre-ERT2 + ERT2-CCre (NE+EC). A: CHO cells were
transfected with different amounts of NE+EC and cultured in the
absence (control, open bars) or presence of 4OHT (1 mM, black bars).
Recombination was analyzed by luciferase reporter expression. The
luminescence of reporter-only transfected cells (1.860.3%; n=15) was
subtracted from all values. B: CHO cells were transfected with 100 ng
each of NE+EC and cultured in the presence of different concentrations
of 4OHT. Luminescence in A and B was normalized to the luminescence
observed in N+C transfected cells (100 ng of each plasmid/well) in the
absence of 4OHT, which was set as 100%. C: PC12 20.4 cells were
transfected with different amounts of NE+EC and cultured in the
absence (control, open bars) or presence of 4OHT (1 mM, black bars).
Recombination was analyzed by EGFP reporter expression using flow
cytometry. The percentage of EGFP
+-cells observed in the absence of
NE+EC (4.460.7%; n=9) was subtracted from all values. D: Cells were
transfected with NE+EC plasmids (400 ng each/well) and cultured in the
presence of different concentrations of 4OHT. The number of EGFP-
positive cells in C and D was normalized to the number of EGFP-positive
cells in N+C transfected cultures (400 ng of each plasmid/well) in the
absence of 4OHT, which was set as 100%. All panels summarize data
from a minimum of 3 independent experiments, each of which was
performed at least in triplicate.
doi:10.1371/journal.pone.0008354.g006
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same range as determined for split-CreERT2 and both of these
inducible Cre versions have been used successfully in mice in vivo
(for example: CreERT: [18–22]; CreERT2: [22–28]; for overview:
[29]), the tissue concentrations of tamoxifen will most likely be
sufficient for efficient induction of split-CreERT2.
Split-CreERT2 allows controlling DNA recombination spatially
by the simultaneous activity of two promoters and temporally by
application of tamoxifen. Similar criteria are met by another
inducible recombination system based on Cre protein fragment
complementation [30,31]. In this approach, the dimerization of
Cre fragments is regulated by rapamycin dependent interaction of
FKBP- and FRB-protein domains. When expressed in mice driven
by two constitutively active promoters, partial DNA recombina-
tion could be observed in several tissues including liver, kidney and
heart. However, no recombination was observed in brain, muscle
or epidermis [31]. At least for the brain, this might well be due to
the poor blood-brain barrier permeability of rapamycin. In
addition, rapamycin might have several side effects due to its
function as immunosuppressant. Split-CreERT2 proteins are
supposed to interact constitutively when co-expressed within a
cell due to the constitutively active GCN4 protein-protein
interaction domain [15], but the translocation to the nucleus is
regulated by tamoxifen as described for CreERT2 [23,24]. While
tamoxifen might also have some side effects via various
mechanisms [32–35] it has already been used successfully to
induce DNA recombination in numerous tissues including the
brain [29]. This profound experience with experimental strategies
for tamoxifen application, with kinetics of recombination, tissue
specificity etc. will facilitate the transfer of the split-CreERT2
system into mice in vivo. While the function of split-CreERT2 in
living mice remains to be demonstrated, it is very likely that split-
CreERT2 - given this enormous potential - will be a significant
addition to the toolbox of modern mouse genetics.
Materials and Methods
Cloning
The pCMV-Tag2B-NCre- and pCMV-Tag3B-CCre-plasmids
have been recently described in detail [15]. To generate pERT2-
NCre and pERT2-CCre, a PCR was performed using pCreERT2
as template and the primers 59-GAGAGGATCCTCTGCTG-
GAGACATGAGAGC-39 and 59-GAGAGGATCCGCTGCCG-
TTGCTGGCGCCAGGGTTGCTAGGGCTGGCGACTGTG-
GCAGGGAAACCC-39. BamHI restriction sites were added to
the 59- and 39-end of the coding sequence of the ERT2-domain by
PCR. In addition, a linker sequence (amino acid sequence
ASPSNPGASNGS) [15] was added to connect the ERT2-domain
and the NCre- or CCre part of the fusion protein. The PCR
product was cloned into the BamHI restriction site of pCMV-
Tag2B-NCre and pCMV-Tag3B-CCre (all restriction enzymes
used were from Fermentas, St.Leon-Rot, Germany).
To generate pNCre-ERT2 and pCCre-ERT2-constructs, the
Stop codon within pCMV-Tag2B-NCre- and pCMV-Tag3B-
CCre-plasmids was removed and a SpeI restriction site was
introduced at the 39-end of the NCre- or CCre open reading
frame. To do this, PCR was performed using the primers 59-
GAGAGAATTCAGCGGCCCTCCCA-39 and 59-GAGAAAG-
CTTACTAGTGTTCAGCTTGCACCAGGCA-39 and pCMV-
Tag2B-NCre as template. The PCR product was digested using
EcoRI and HindIII and cloned into the EcoRI/HindIII restriction
sites of pCMV-Tag2B-NCre. To modify pCMV-Tag3B-CCre
accordingly, primers 59-TCCACAGCTGGTGTGGAGAA-39
and 59-GAGAAAGCTTACTAGTGTCCCCATCCTCGAG-
CAG-39 were used with pCMV-Tag3B-CCre as template. The
PCR-product was digested using BstEII and HindIII and cloned
into the BstEII/HindIII restriction sites of pCMV-Tag2B-NCre.
Finally, a PCR was performed using primers 59-GAGAAC-
TAGTTCTGCTGGAGACATGAGAGC-39 and 59-GAGAAC-
TAGTTCAGACTGTGGCAGGGAAACCC-39 with pCreERT2
as template to add a SpeI restriction site to both ends of the ERT2
domain as well as a Stop codon to the 39-end of the ERT2 open
reading frame. This PCR product was digested using SpeI and
cloned into the SpeI restriction site introduced as described above
at the 39-end of pCMV-Tag2B-NCre- and pCMV-Tag3B-CCre-
open reading frames. All constructs were verified by restriction
analysis and sequencing.
Cell Culture, Transfection and Analysis of Recombination
CHO cells (DSMZ, Braunschweig, Germany) were cultured in
Ham’s F12 (PAA, Co ¨lbe, Germany), 2 mM glutamine (Roth,
Karlsruhe, Germany), 10% fetal calf serum (Biochrom, Berlin,
Germany), 50 units/mL penicillin G (Sigma-Aldrich, Steinheim,
Germany), 50 mg/mL streptomycin (Sigma-Aldrich) and seeded
on 96-well cell culture plates (20000 cells/well) for luciferase
assays. Cells were transfected the next day using Lipofectamin
2000 (Invitrogen, Karlsruhe, Germany) with 100 ng or the
indicated amount (Fig. 6A) of each split-CreERT2 plasmid/well.
For reporter-only controls, the same amount of an empty vector
was transfected. For analysis of Cre-dependent recombination, a
CMV-LoxP-STOP-LoxP-firefly luciferase reporter plasmid was
cotransfected (100 ng/well). In addition, to normalize for
transfection efficiency, a mixture of plasmids coding for renilla
luciferase (total 50 ng/well; CMV-RL, TK-RL and SV40-RL at
1:2:10 molar ratio) was cotransfected as described [16] and the
ratio of firefly luciferase activity to renilla luciferase activity was
calculated. 24 h after transfection, 4OHT (Sigma-Aldrich; 1 mM
or the indicated concentration (Fig. 6B)) was added and luciferase
activity was measured a further 48 h later using a Lumistar
microplate reader (BMG Labtech, Offenburg, Germany).
PC12 20.4 cells [16] contain a stably integrated CMV-LoxP-
STOP-LoxP-EGFP cassette which enables analysis of Cre
mediated DNA recombination by EGFP fluorescence. Cells were
cultured in RPMI 1640 (PAA), 5% fetal calf serum, 10% horse
serum, 2 mM glutamine, 50 units/mL penicillin G, 50 mg/mL
streptomycin, 10 mM HEPES (Roche, Mannheim, Germany),
25 mM glucose (Roth), 15 mM NaHCO3 (Roth), 1 mM sodium
pyruvate (Sigma-Aldrich). For experiments cells were seeded on
24-well cell culture plates (60000 cells/well) and transfected the
day after plating using Lipofectamin 2000 (Invitrogen) with 400 ng
or the indicated amount (Fig. 6C) of each split-CreERT2 plasmid/
well. For reporter-only controls, the same amount of an empty
vector was transfected. 24 h after transfection, 4OHT (1 mMo r
the indicated concentration (Fig. 6D)) was added. A further 48 h
later, cells were harvested by trypsinization and analyzed for
EGFP expression using flow cytometry (LSR II, BD Biosciences,
Heidelberg, Germany).
Western Blotting
CHO cells were seeded in 6-well culture plates (1000000 cells/
well) and transfected the next day using Lipofectamin 2000
(Invitrogen) with 4 mg of each plasmid/well. For vector-transfected
controls, the same amount of an empty vector was transfected.
24 h after transfection, 4OHT (1 mM) was added and cell lysates
were prepared 48 h later in lysis buffer (10 mM Tris/HCl, 5 mM
EDTA, pH 7.4) supplemented with Complete protease inhibitor
cocktail (Roche, Mannheim, Germany). Samples were homoge-
nized using a sonicator and protein content was assayed with BCA
Split-CreERT2
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sample buffer (375 mM Tris/HCl, pH 6.8, 5% SDS, 12%
glycerol, 0.05% bromophenol blue, 10% b-mercaptoethanol)
and heated for 30 min at 50uC (detection of Myc-tag) or for
10 min at 85uC (all other antibodies). 15 mg of protein per lane
were separated by SDS-PAGE and blotted onto a nitrocellulose
membrane (Amersham, Brussel, Belgium). Membranes were
blocked with 5% milk powder and 10% Roti-Block (Roth) in
PBS (pH 7.4) and incubated with the following primary
antibodies: mouse anti-GAPDH (1:1000; Ambion, Foster City,
USA), mouse anti-Myc tag (1:500; Sigma-Aldrich), HRP-conju-
gated mouse anti-Flag tag (1:1000; Sigma-Aldrich), rabbit anti-Cre
(1:1000; Covance, Princeton, USA). The following secondary
antibodies were used: HRP-conjugated goat anti-mouse IgG
(1:1000; Dianova, Hamburg, Germany) and HRP-conjugated goat
anti-rabbit IgG (1:1000; Santa Cruz Biotechnology, Heidelberg,
Germany). All antibodies were diluted in 5% milk powder in PBS
(pH 7.4).
Immunocytochemical Analysis
For immunocytochemical analysis, CHO cells (60000 to 100000
cells/well) were cultured on glass coverslips in 24-well cell culture
plates. Cells were transfected one day after plating with the
following plasmids: NE and EC (150 or 400 ng each/well), a
reporter plasmid expressing EGFP after Cre-mediated DNA
recombination (400 ng/well) and in some cases (Fig. 5A, B) with
pCMV-DsRedNuc (100 ng/well) using Lipofectamin 2000 (In-
vitrogen). 24 h after transfection, 4OHT (1 mM) was added. 48 h
later, cells were fixed for 10 min in 4% paraformaldehyde (Fig. 5A,
B) or for 10 min with 1% paraformaldehyde and 10 min with
MeOH at 220uC (Fig. 5C–F). Immunostaining was performed
using the following antibodies: Fig. 5A, B: rabbit anti-GFP (1:500;
Abcam, Cambridge, UK) and Cy2-conjugated goat anti-rabbit
IgG (1:1000; Dianova). Fig. 5C–F: mouse anti-Myc (1:5000;
Sigma-Aldrich); rabbit anti-Flag (1:1000; Rockland, Gilbertsville,
PA, USA), goat anti-GFP (1:2000; Rockland); Cy3-conjugated
donkey anti-mouse IgG (1:5000; Dianova); Cy5-conjugated
donkey anti-rabbit IgG (1:400; Dianova) as well as Cy2-conjugated
donkey anti-goat IgG (1:1000; Dianova). Fluorescence images
were acquired on an Axiovert 200 fluorescence microscope (Zeiss,
Oberkochen, Germany) using either a Plan-Apochromat 63x/1.40
or a Fluar 40x/1.30 objective (both from Zeiss).
Presentation of Data
Figures were generated using Sigmaplot 10.0 (Systat, Erkrath,
Germany) and statistical tests were performed using SigmaStat 3.5
(Systat). All data are given as mean6standard error of the mean
(SEM). Microscopic images were processed using Axiovision
software (Zeiss) and Adobe Photoshop. Final illustrations were
arranged using Adobe InDesign.
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